A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151

• Research type

  Research Study

• Full title

  A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Recurrent Gynaecological Cancers.

• IRAS ID

  1009320

• Contact name

  Gemma Macdonald

• Contact email

  gemma.macdonald@ergomedgroup.com

• Sponsor organisation

  ImmunoGen, Inc.

• Eudract number

  2023-506842-22

• Clinicaltrials.gov Identifier

  NCT05527184

• Research summary

  First in Human study of IMGN151 antibody monoclonal antibodies in patients with recurrent Gynaecological cancers. This study aims to understand the safety tolerability, how the drug moves through the body (pharmacokinetics), immune reactions triggered by the study drug (immunogenicity), and its early effectiveness in treating the specified types of cancer. This study also involves evaluating how well IMGN151 works in terms of shrinking tumors according to radiological criteria. Patients may or may not directly benefit from this study. Patients participation in the study may help to understand how IMGN151 works. This may help to find out if IMNG151 is safe to give to patients who have recurrent cancer.

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  25/NE/0068

• Date of REC Opinion

  11 Jun 2025

• REC opinion

  Further Information Favourable Opinion